GLP1R and type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists (GLP-1RAs)2,3 and sodium glucosecotransporter 2 inhibitors (SGLT2i)4 have been shown to improve glucose control, lead to weight loss, andreduction in cardiovascular and renal events in patients with type 2 diabetesmellitus (T2DM), and therefore current treatment guidelines widely recommend theiruse in those with T2DM.